NEXS Technology Group Joins AWS Startup Program, Accelerating the Fight Against Cancer

ELKRIDGE, Md. - Feb. 26, 2025 - PRLog -- NEXS Technology Group is excited to announce its acceptance into the prestigious AWS Startup Program, a significant milestone that will propel the development and deployment of CancerScope-AI, our state-of-the-art artificial intelligence tool. Developed in close collaboration with our sister company, NEXS BioMedica Corporation, CancerScope-AI is set to transform cancer research and personalized treatment by harnessing advanced machine learning to analyze rare cancer data.

CancerScope-AI leverages multi-omics and clinical datasets, including information from The Cancer Genome Atlas (TCGA), to predict treatment responses with over 75% accuracy and identify key biomarkers for targeted drug development. This innovative platform is designed to fill the critical gap in rare cancer diagnostics and therapy—a field often underserved by conventional oncology tools.

"Being accepted into the AWS Startup Program is a testament to our commitment to innovation in healthcare," said Dr. Marc Nelson, Chief Executive Officer and Inventor of CancerScope-AI. "The support and resources provided by AWS will enhance our cloud capabilities, allowing CancerScope-AI to deliver real-time, actionable insights that empower clinicians and researchers in the fight against cancer. Our collaboration with NEXS BioMedica Corporation underscores our joint vision to leverage cutting-edge technology in developing personalized treatments for patients."

Utilizing key AWS services, such as Amazon EC2 for scalable compute power, Amazon S3 for secure data storage, and AWS Lambda for serverless computing, CancerScope-AI is built to efficiently handle large datasets and complex analytical tasks. The platform also features an interactive dashboard powered by Dash and Plotly, offering intuitive visualization of treatment predictions and biomarker rankings.

NEXS BioMedica Corporation, our sister company, plays a pivotal role in translating these technological advancements into clinical and pharmaceutical innovations. Together, we are committed to addressing unmet medical needs in rare cancer treatment and accelerating the development of precision therapies that improve patient outcomes.

For more information on our groundbreaking work and our participation in the AWS Startup Program, please visit NEXS Technology Group (https://www.nexstechnology.com) and learn more about AWS Startups (https://aws.amazon.com/startups).

About NEXS Technology Group
NEXS Technology Group is a pioneering technology innovator dedicated to transforming healthcare through advanced data analytics and artificial intelligence. Our mission is to empower clinicians and researchers with innovative tools that drive personalized medicine and improve patient outcomes.

About NEXS BioMedica Corporation
NEXS BioMedica Corporation, our sister company, is at the forefront of biomedical research and drug development. By leveraging cutting-edge technologies and data-driven insights, NEXS BioMedica is committed to pioneering new approaches in cancer treatment and advancing precision medicine.

Media Contact:
Marc Nelson, MD
Chief Executive Officer
NEXS Technology Group
Email: info@nexstechnology.com
Phone: 571-580-2911